Morria Biopharmaceuticals Plc Announces Promising Pre-Clinical Results in Inflammatory Bowel Disease (IBD).LONDON -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs Non-steroidal anti-inflammatory drugs (NSAIDs) Aspirin, ibuprofen, naproxen, and many others. Mentioned in: Mastocytosis , announced today that its leading oral drug candidate, MRX-5, markedly ameliorated IBD IBD abbr. inflammatory bowel disease Inflammatory bowel disease (IBD) Disease in which the lining of the intestine becomes inflamed. Mentioned in: Amebiasis IBD 1. symptoms in independently-conducted pre-clinical studies in animals. The studies were conducted using the DSS (1) (Digital Signature Standard) A National Security Administration standard for authenticating an electronic message. See RSA and digital signature. (2) (Digital Satellite S mouse model, a standard industry model that mimics the effects of IBD. MRX-5 was given orally in several concentrations for up to 7 days of co-treatment with the disease-inducing stimulus. Morbidity was measured by weight loss, intestinal length and intestinal permeability. MRX-5 significantly improved all morbidity parameters and no adverse effects were noted in a parallel safety study. "We are very pleased with this important milestone" said Dr. Yuval Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , Managing Director of Morria Biopharmaceuticals. "It demonstrates the tremendous broad-range potential of our leading drug candidates and follows on recent similar milestones in skin and lung inflammation. IBD is one of our three core indications and we plan to continue its pre-clinical development and prepare a regulatory submission for human studies". ABOUT IBD IBD is a chronic, incurable, life-long condition that features relapsing inflammation of the gastrointestinal tract gastrointestinal tract n. The part of the digestive system consisting of the stomach, small intestine, and large intestine. Gastrointestinal tract and includes Crohn's disease Crohn's disease: see colitis. and ulcerative colitis ulcerative colitis Inflammation of the colon, especially of its mucous membranes. The inflamed membranes develop patches of tiny ulcers, and the diarrhea contains blood and mucus. . Over 2 million patients are affected in the world's seven major pharmaceutical markets, spending in excess of $2bn a year on treatment. Current drugs are often associated with severe side-effects making them unsuitable for chronic treatment. MRX-5 is Morria's first in class oral lead drug candidate for IBD. ABOUT MORRIA BIOPHARMACEUTICALS Plc Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs Anti-inflammatory drugs A class of drugs that lower inflammation and that includes NSAIDs and corticosteroids. Mentioned in: Antirheumatic Drugs (MFAID). Morria is determined to use its unique technological and cost advantage to become a major player in the $50bn anti-inflammatory drug market within the next decade through the introduction of novel drugs for the treatment of a variety of chronic inflammatory conditions including skin, lung and gastro-intestinal inflammatory diseases. This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion